Stability of relevant plasma protein activities in cryosupernatant plasma units during refrigerated storage for up to 5 days postthaw

Transfusion

Volumn 54, Issue 2, 2014, Pages 418-425

  Bhakta, Varsha ^a   Jenkins, Craig ^a   Ramirez Arcos, Sandra ^a   Sheffield, William P ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEINS; BLOOD BANKS; BLOOD COAGULATION FACTORS; BLOOD PRESERVATION; CRYOPRESERVATION; FACTOR V; FACTOR VII; FACTOR VIII; FIBRINOGEN; HUMANS; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 84893959326     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12254     Document Type: Article

References (40)

1. Pool JG, Gershgold EJ, Pappenhagen AR,. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature 1964; 203: 312.
2. Callum JL, Karkouti K, Lin Y,. Cryoprecipitate: the current state of knowledge. Transfus Med Rev 2009; 23: 177-188.
3. Canadian Blood Services. Circular of Information (Plasma components). Ottawa (ON): Canadian Blood Services; 2012. p. 1.
4. Grobler C, Callum J, McCluskey SA,. Reversal of vitamin K antagonists prior to urgent surgery. Can J Anaesth 2010; 57: 458-467.
5. Radhi M, Carpenter SL,. Thrombotic microangiopathies. ISRN Hematol 2012; 2012: 310596.
6. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B,. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
7. Tsai HM, Lian EC,. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
8. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM,. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
9. Tsai HM,. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010; 91: 1-19.
10. Liu F, Huang J, Sadler JE,. Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways. Blood 2011; 118: 3392-3398.
11. Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, Nurnberger J, Gerke P, Wiesner M, Sucke B, Abu-Tair M, Kribben A, Klause N, Schindler R, Merkel F, Brunkhorst R, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012; 27: 3807-3815.
12. Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM,. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 53: 259-272.
13. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V,. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643-657.
14. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA,. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-397.
15. Rock G, Shumak KH, Sutton DM, Buskard NA, Nair RC,. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol 1996; 94: 383-386.
16. Rock G, Anderson D, Clark W, Leblond P, Palmer D, Sternbach M, Sutton D, Wells G,. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005; 129: 79-86.
17. Zeigler ZR, Shadduck RK, Gryn JF, Rintels PB, George JN, Besa EC, Bodensteiner D, Silver B, Kramer RE,. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher 2001; 16: 19-22.
18. Serrano K, Scammell K, Weiss S, Culibrk B, Levin E, Gyongyossy-Issa M, Devine DV,. Plasma and cryoprecipitate manufactured from whole blood held overnight at room temperature meet quality standards. Transfusion 2010; 50: 344-353.
19. Levin E, Culibrk B, Gyongyossy-Issa MI, Weiss S, Scammell K, LeFresne W, Jenkins C, Devine DV,. Implementation of buffy coat platelet component production: comparison to platelet-rich plasma platelet production. Transfusion 2008; 48: 2331-2337.
20. Canadian Blood Services. Circular of Information (with Amendments 1 & 2, May 2007). Ottawa (ON): Canadian Blood Services; 2005. p. 61.
21. Canadian Standards Association. CAN/CSA-Z902-10. Blood and blood components: Canadian Standards Association, 2010: 37.
22. British Committee for Standards in Haematology. Guidelines for the use of fresh frozen plasma (updated). Br J Haematol 2004; 126: 11-28.
23. Council of Europe. Guide to the preparation, use and quality assurance of blood components: recommendation No. R (95) 15. 13th ed. Strasbourg: Council of Europe Publishing; 1997.
24. American Association of Blood Banks. Standards for blood banks and transfusion services. 27th ed. Bethesda (MD): American Association of Blood Banks; 2011.
25. Yarranton H, Lawrie AS, Mackie IJ, Pinkoski L, Corash L, Machin SJ,. Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light. Transfusion 2005; 45: 1453-1458.
26. Scott EA, Puca KE, Pietz BC, Duchateau BK, Friedman KD,. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion 2007; 47: 120-125.
27. Rock G, Yousef H, Neurath D, Lu M,. ADAMTS-13 levels in fresh, stored, and solvent detergent treated plasma. Transfus Apher Sci 2006; 35: 235-238.
28. Sheffield WP, Bhakta V, Jenkins C, Devine DV,. Conversion to the buffy coat method and quality of frozen plasma derived from whole blood donations in Canada. Transfusion 2010; 50: 1043-1049.
29. Sheffield WP, Bhakta V, Mastronardi C, Ramirez-Arcos S, Howe D, Jenkins C,. Changes in coagulation factor activity and content of di(2-ethylhexyl) phthalate in frozen plasma units during refrigerated storage for up to five days after thawing. Transfusion 2012; 52: 493-502.
30. Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L,. Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors. Blood Coagul Fibrinolysis 2005; 16: 597-605.
31. Kokame K, Matsumoto M, Fujimura Y, Miyata T,. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004; 103: 607-612.
32. Moore JC, Hayward CP, Warkentin TE, Kelton JG,. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001; 98: 1842-1846.
33. Mastronardi C, Perkins H, Derksen P, denAdmirant M, Ramirez-Arcos S,. Evaluation of the BacT/ALERT 3D system for the implementation of in-house quality control sterility testing at Canadian Blood Services. Clin Chem Lab Med 2010; 48: 1179-1187.
34. Szanto T, Joutsi-Korhonen L, Deckmyn H, Lassila R,. New insights into von Willebrand disease and platelet function. Semin Thromb Hemost 2012; 38: 55-63.
35. O'Neill EM, Rowley J, Hansson-Wicher M, McCarter S, Ragno G, Valeri CR,. Effect of 24-hour whole-blood storage on plasma clotting factors. Transfusion 1999; 39: 488-491.
36. Street A,. Developing models of haemophilia care. Haemophilia 2012; 18 (Suppl 4): 89-93.
37. Zhou Z, Yeh HC, Jing H, Wang C, Tao Z, Choi H, Aboulfatova K, Li R, Dong JF,. Cysteine residues in CUB-1 domain are critical for ADAMTS13 secretion and stability. Thromb Haemost 2011; 105: 21-30.
38. Song MM, Warne CP, Crowther MA,. Prothrombin complex concentrate (PCC, Octaplex) in patients requiring immediate reversal of vitamin K antagonist anticoagulation. Thromb Res 2012; 129: 526-529.
39. Kakaiya RM, Morse EE, Panek S,. Labile coagulation factors in thawed fresh frozen plasma prepared by two methods. Vox Sang 1984; 46: 44-46.
40. Smak Gregoor PJ, Harvey MS, Briet E, Brand A,. Coagulation parameters of CPD fresh-frozen plasma and CPD cryoprecipitate-poor plasma after storage at 4 degrees C for 28 days. Transfusion 1993; 33: 735-738.